(Approval lapsed) ABRAXANE paclitaxel 100mg/20mL powder for injection (suspension) (Brazil)
Section 19A approved medicine
(Approval lapsed) ABRAXANE paclitaxel 100mg/20mL powder for injection (suspension) (Brazil)
Section 19A approval holder
Specialised Therapeutics Australia Pty Ltd ABN: 73 124 031 241
Phone
1300 798 820
Approved until
Status
Expired
Medicines in short supply/unavailable
ABRAXANE nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial - AUSTR 133500
Indication(s)
- Metastatic Breast Cancer - ABRAXANE is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy
- Non-small Cell Lung Cancer - ABRAXANE, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation
- Metastatic Adenocarcinoma of the Pancreas - ABRAXANE, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas